Angiogenic inhibitors: a new therapeutic strategy in oncology

Area of Science:

• Oncology
• Pharmacology

Background:

• Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
• Antiangiogenic compounds can modify tumor endothelium, potentially enhancing cytotoxic drug delivery.
• Preclinical data suggests antiangiogenic agents hold promise for cancer therapy.

Purpose of the Study:

• To review the pharmacodynamic and pharmacokinetic characteristics of antiangiogenic drugs.
• To summarize clinical studies of antiangiogenic agents in cancer treatment.
• To highlight challenges in the clinical development of antiangiogenic therapies.

Main Methods:

• Review of preclinical models and clinical trial data.
• Analysis of pharmacodynamic and pharmacokinetic properties of antiangiogenic drugs.
• Examination of Phase III trials comparing chemotherapy alone versus combination therapy.

Main Results:

• Early clinical trials showed promising antitumor activity but faced challenges.
• Recent large-scale trials with anti-vascular endothelial growth factor antibodies demonstrated significant clinical benefit.
• The efficacy of antiangiogenic agents varies, with some studies yielding controversial or negative results.

Conclusions:

• Antiangiogenic therapy, especially with anti-VEGF antibodies, offers significant clinical benefit in cancer treatment.
• Further research is needed to optimize patient selection, study design, and endpoint selection for antiangiogenic drug development.
• The review underscores the renewed enthusiasm and potential of angiogenesis inhibitors in oncology.